An inhibitor that targets a specific mutation in relapsed or refractory acute myeloid leukaemia improves the survival rate of patients, a major conference has been told. The phase III ADMIRAL trial, led by a team at the Abramson...
12 days ago
Researchers investigating acute erythroid leukaemia have identified five sub-groups of the condition that have distinct gene mutations and patient outcomes. The diagnostic criteria for acute erythroid leukaemia have changed over...
12 days ago